Compass Oncology

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

Louis Fehrenbacher, Alexander I. Spira, Marcus Ballinger et al. · The Lancet · 2016 · 2.8K citations

Non-small-cell Lung Cancer, Medicine, Metronomic Therapy +9

Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA

M.C. Liu, Geoffrey R. Oxnard, Eric A. Klein et al. · Annals of Oncology · 2020 · 1.4K citations · Full text

Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study

Ian W. Flinn, Richard van der Jagt, Brad S. Kahl et al. · Blood · 2014 · 623 citations · Full text

Boundary spanning at the science–policy interface: the practitioners’ perspectives

Angela Bednarek, Carina Wyborn, Christopher Cvitanovic et al. · Sustainability Science · 2018 · 307 citations · Full text

Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS)

Franck Morschhauser, Ian W. Flinn, Ranjana H. Advani et al. · The Lancet Haematology · 2019 · 243 citations · Full text

Lymphoid Neoplasia, Pinatuzumab Vedotin, Medicine +9